Gilead Sciences (GILD) ended the recent trading session at $91.86, demonstrating a -0.57% swing from the preceding day's closing price. On the other hand, the Dow registered a loss of 0.2%, and the ...
A review found half of the drugs studied had price increases based on new evidence of benefits, while the other half did not.
The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...
In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.
The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for ...
The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the ...
El Mundo on MSN17h
Drug that protects against HIV with two 'shots' a year, discovery of the year for 'Science'Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
Many HIV/AIDS researchers are hopeful that the drug, developed by American biopharmaceutical company Gilead Sciences, will powerfully drive down global infection rates when used as pre-exposure ...
The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from ...
California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback